Y-Mabs Therapeutics Updates on Radiopharmaceutical Progress

Y-Mabs Therapeutics ( (YMAB) ) just unveiled an update.

On May 28, 2025, Y-mAbs Therapeutics held a virtual research and development update to discuss progress in its Radiopharmaceutical business unit. The company released complete Part A data from its GD2-SADA Phase 1 Clinical Trial, demonstrating the safety and tolerability of GD2-SADA-177 Lu-DOTA. This update marks a significant step in Y-mAbs’ strategy to disrupt the existing radiopharmaceuticals market by addressing key obstacles to commercial utilization, potentially impacting its industry positioning and stakeholder interests.

The most recent analyst rating on (YMAB) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Y-Mabs Therapeutics stock, see the YMAB Stock Forecast page.

Spark’s Take on YMAB Stock

According to Spark, TipRanks’ AI Analyst, YMAB is a Neutral.

Y-Mabs Therapeutics faces significant challenges with profitability and cash flow despite revenue growth. The technical analysis indicates a bearish trend, and the valuation is not compelling due to negative earnings. While the earnings call presented some positive developments, the strategic realignment must address key challenges to improve the outlook.

To see Spark’s full report on YMAB stock, click here.

More about Y-Mabs Therapeutics

Y-mAbs Therapeutics, Inc. is a commercial biopharmaceutical company with two distinct business units: DANYELZA and Radiopharmaceuticals. The company focuses on developing novel cancer treatments, particularly through its proprietary radiopharmaceuticals platform, which aims to minimize off-target effects and enhance patient safety.

Average Trading Volume: 279,471

Technical Sentiment Signal: Sell

Current Market Cap: $199.7M

Find detailed analytics on YMAB stock on TipRanks’ Stock Analysis page.